Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0457 in T315I Mutant CML and Ph+ ALL
NCT00405054Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2006
- Primary completion
- Jun 2009
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tozasertib in chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), sponsored by Merck & Co.. Started Dec 2006; status: terminated.
02
Drugs
tozasertib
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00405054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00405054.